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A tumor, such as a dermatofibroma, causes consternation among many patients, but it rarely creates 
problems on its own. Also called a histiocytoma, it remains one of the most common mesenchymal 
growths. Its etiology is unknown with the previous theory that it is a dermal response to injury, such as 
an insect bite, being challenged. As much as patients like to blame spiders or other arthropods for 
traumatizing an arm or leg, no definitive explanation is available for its etiology. 
This lesion seems more likely to be a neoplastic process due to the persistent nature of the lesion, the 
frequency of local recurrence of some variants, and the clonal proliferative growth suggested by several 
cytogenetic studies (1, 2). Clonality, by itself, is not necessarily synonymous with a neoplastic process, as 
has been demonstrated in several inflammatory conditions, including atopic dermatitis, psoriasis, and 
lichen sclerosis (2). 
A dermatofibroma represents a benign dermal and often superficial subcutaneous proliferation of oval 
cells, appearing as histiocytes and spindle-shaped cells resembling fibroblasts and myofibroblasts (3). It 
occurs four times more often in women and is found in patients of any age, while nearly 80% of the 
patients are between the ages of 20 and 49 years (4). 
CLINICAL FINDINGS 
A dermatofibroma typically arises slowly and as a solitary, 0.5- to 1-cm nodule, frequently yellowish 
brown, and slightly scaly. Fig 1 It is most often found on an extremity, particularly the leg; however, the 
palm, sole, fingers, genitalia, head and neck are not exempt.  Its color may range from pink to red or 
even to tan.  Variations include a diameter, larger than 5 cm (5).  It is usually a solitary lesion, but several 
dermatofibromas may also be present, only rarely multiple (i.e., 15 or more) tumors, most frequently in 
the setting of an autoimmune disease or altered immunity. 
The diagnosis is easily made on inspection, with palpation revealing a hard nodule. If the overlying 
epidermis is squeezed, the “dimple sign” will be seen due to tethering of the overlying epidermis to the 
underlying lesion further confirming the diagnosis. This has also been called the Fitzpatrick sign and may 
also be elicited by placing an ice cube over the lesion. (6) 
A dermatofibroma is usually asymptomatic, but itching and pain are occasionally noted. Significant 
trauma may cause ulceration.   
The differential diagnosis is extensive but some lesions that might offer confusion, due to similarity of 
appearance and consistency, are listed in Table 1.  A tumor that might warrant excision to prove its 
benign nature is a juvenile xanthogranuloma, where feeling the firm consistency will discount this lesion.  
Palpation of one or more hard nodules especially on the trunk may raise the suspicion of 
dermatofibrosarcoma protuberans, which can be differentiated by histopathology and 
immunohistochemical testing.  Traumatizing the lesion with subsequent erosion and ulceration may lead 
to the misdiagnosis of squamous cell carcinoma or even atypical fibroxanthoma. 
 
Table 1. Differential diagnosis of dermatofibroma. 
Differential Diagnosis of Dermatofibroma 
Melanocytic nevus 
Blue nevus  
Dermatofibrosarcoma protuberans 
Juvenile xanthogranuloma 
Keloid and hypertrophic scar  
Keratoacanthoma 
Leiomyoma 
Malignant melanoma  
Mastocytosis 
Metastatic carcinoma of the skin  
Neurilemoma 
Pilomatrixoma 
Prurigo nodularis 
Spitz nevus 
Squamous cell carcinoma  
Atypical fibroxanthoma 
 
Diagnosis 
The diagnosis of a dermatofibroma is predominantly clinical.  Dermatoscopy may be useful, when 
revealing the most common pattern of a peripheral pigment network, along with a central white area 
(7). In the case of any diagnostic uncertainty, an excisional biopsy with removal of the subcutaneous fat 
would be indicated. 
Histopathologic examination will reveal epidermal hyperplasia and hyperpigmetation of the basal cell 
layer (“dirty fingernail” sign).  The bulk of the tumor is within the mid-portion of the dermis without any 
capsule formation.  (Figs 2 and 3)Whorling fascicles of spindle cell proliferation with excessive collagen 
deposition are characteristic. Some histologic variants of dermatofibroma have been described, as seen 
in Table 2; however, the clinical picture is generally within the characteristic limits.  Results from 
immunohistochemical testing with antibodies to factor XIIIa are frequently positive in dermatofibroma. 
 
 
 
 
 
Table 2. Histologic variants of dermatofibroma. 
Histologic Variants of Dermatofibroma 
Cellular (8) 
Aneurysmal(9) 
Atypical (dermatofibroma with monster cells)(10) 
Epithelioid(11) 
Atrophic(12) 
Polypoid(13)  
Dermatofibroma with spreading satellitosis (14) 
Deep (subcutaneous) dermatofibroma 
   
Treatment 
A dermatofibroma is considered a benign lesion with a good prognosis.  Although unusually rapid 
growth may occur, most dermatofibromas remain static for many years.  Spontaneous regression has 
been reported which may result in post inflammatory hypopigmentation.  Aggressive subtypes (cellular, 
aneurysmal, atypical, and deep/subcutaneous) locally recur in up to 20% of the patients and rarely 
metastasize.  Although these variants are definitely diagnosed histopathologically, some clinical findings 
may raise suspicion. For example, an abnormally large size of the lesion, especially measuring more than 
5cm and rapid growth, may be indicative of a cellular or aneurysmal dermatofibroma.  An unusual 
appearance mimicking a vascular tumor can be a leading sign to an aneurysmal subtype. 
No treatment is usually necessary for dermatofibromas.  The scar resulting from excision is sometimes 
more noticeable than the original lesion especially on the leg, so simple reassurance that the lesion is 
benign may be indicated.  Complete excision, including the subcutaneous fat, is ideal for symptomatic 
ones, where a cosmetically unacceptable lesion may be the end result of intervention done at the 
request of the patient.  Superficially shaving of the lesion or cryosurgery can be attempted; however, 
recurrences are more likely, and the cosmetic results are not necessarily better.  Intralesional steroid 
injections have been used with variable results. Carbon dioxide laser surgery for multiple facial 
dermatofibromas has also been utilized (15), while an effective and safe therapeutic option could be use 
of the pulsed dye laser (PDL) (16). 
Conclusions 
A dermatofibroma remains slightly more than a cosmetic nuisance. If it looks within normal 
limits, excision just for cosmetic purposes is not recommended; however, if any uncertainty 
exists about an unusual appearance, an abnormally large size, any irregularity, or unusual 
location, excision should be considered. In these circumstances, the lesion might be better 
being studied by the dermatopathologist, instead of remaining on the patient’s body. 
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Figure 1  Clinical appearance of a dermatofibroma 
Figure 2 
Figure 3 
